Pfizer hands back Bavencio rights as Seagen acquisition nears

27 March 2023
bavencio_merck_large

Germany’s Merck KGaA (MRK: DE) has regained exclusive worldwide rights to develop, manufacture, and commercialize its checkpoint blocker Bavencio (avelumab).

The news comes just a couple of weeks after erstwhile co-developer Pfizer (NYSE: PFE) announced plans to buy antibody-drug conjugate (ADC) company Seagen (Nasdaq: SGEN), at a price of $43 billion.

That acquisition was likely to require the divestment of Pfizer’s interests in Bavencio in order to satisfy antitrust bodies, given the overlap with Seagen’s Padcev (enfortumab vedotin-ejfv), a first-in-class ADC approved in bladder cancer.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology